Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia

Psychiatry Research

Volumn 77, Issue 3, 1998, Pages 159-166

  Magharious, Wagdan ^a   Goff, Donald C ^b,c   Amico, Edward ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; NEUROLEPTIC AGENT; PROLACTIN;

ADULT; AKATHISIA; AMENORRHEA; ARTICLE; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MENSTRUAL IRREGULARITY; MENSTRUATION; PREMENOPAUSE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYMPTOMATOLOGY;

ADULT; AMENORRHEA; ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MENSTRUAL CYCLE; MIDDLE AGED; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEX FACTORS;

EID: 0032570921     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-1781(97)00137-6     Document Type: Article

References (44)

1. Angermeyer M.C., Goldstein J.M., Kuehn L. Gender differences in schizophrenia: rehospitalization and community survival. Psychological Medicine. 19:1989;365-382.
2. Angermeyer M.C., Kuhn L., Goldstein J.M. Gender and the course of schizophrenia: differences in treated outcomes. Schizophrenia Bulletin. 16:1990;293-307.
3. Ayd F.J. Jr. A survey of drug-induced extrapyramidal reactions. Journal of the American Medical Association. 175:1961;1054-1060.
4. Baldessarini, R.J., 1985. Chemotherapy in Psychiatry. Harvard University Press, Cambridge.
5. Beumont P.J.V., Gelder M.G., Friesen H.G., Harris G.W., MacKinnon P.C.B., Mandelbrote B.M., Wiles D.H. The effects of phenothiazines on endocrine function: I. British Journal of Psychiatry. 124:1974;413-419.
6. Brown W.A., Laughren T.P. Tolerance to the prolactin-elevating effect of neuroleptics. Psychiaty Research. 5:1981;317-322.
7. Carter D.A., McGarrick G.M., Norton K.R.W., Paykel E.S., Prysor-Jones R.A., Whitehead S.A. The effect of chronic neuroleptic treatment on gonadotrophin release. Psychoneuroendocrinology. 7:1982;201-207.
8. Chang S., Renshaw D.C. Psychosis and pregnancy. Comprehensive Therapy. 12:1986;36-41.
9. Childers S.E., Harding C.M. Gender, premorbid social functioning and long-term outcome in DSM-III schizophrenia. Schizophrenia Bulletin. 16:1990;309-318.
10. De Rivera J.L., Lal S., Ettigi P., Hontela S., Muller H.F., Friesen H.G. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clinical Endocrinology. 5:1976;273-282.
11. Endo M., Daiguji M., Asano Y., Yamashita I., Takahashi S. Periodic psychosis recurring in association with menstrual cycle. Journal of Clinical Psychiatry. 39:1978;456-466.
12. Fields J.Z., Gordon J.H. Estrogen inhibits the dopaminergic supersensitivity induced by neuroleptics. Life Sciences. 30:1982;229-234.
13. Friesen, H.G., Erzin, C., Godden, J. et al. (Eds.), 1977. Clinical Endocrinology: A Survey of Current Practice. Appleton-Century-Crofts, New York.
14. Gattaz W.F., Vogel P., Riecher-Rossler A., Soddu G. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biological Psychiatry. 36:1994;137-139.
15. Gerada C., Reveley A. Schizophreniform psychosis associated with the menstrual cycle. British Journal of Psychiatry. 152:1988;700-702.
16. Ghadirian A.M., Chouinard G., Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. Journal of Nervous and Mental Disease. 170:1982;463-467.
17. Glick I.D., Stewart D. A new drug treatment for premenstrual exacerbation of schizophrenia. Comprehensive Psychiatry. 21:1980;281-287.
18. Goff D.C., Henderson D.C., Amico E. Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. American Journal of Psychiatry. 149:1992;1189-1194.
19. Goldstein J.M., Faraone S.V., Chen W.J., Tolomiczencko G.S., Tsuang M.T. Sex differences in the familial transmission of schizophrenia. British Journal of Psychiatry. 156:1990;819-826.
20. Goldstein J.M., Santangelo S.L., Simpson J.C., Tsuang M.T. The role of gender in identifying subtypes of schizophrenia: A latent class analytic approach. Schizophrenia Bulletin. 16:1990;263-275.
21. Hafner H., Behrens S., De Vry J., Gattaz W.F. An animal model for the effects of estradiol on dopamine-mediated behavior: implications for sex differences in schizophrenia. Psychiatry Research. 38:1991;125-134.
22. Igarashi Y., Higuchi T., Toyoshima R., Noguchi T., Moroji T. Tolerance to prolactin secretion in the long-term treatment with neuroleptics in schizophrenia. Advances in Biochemical Psychopharmacology. 40:1985;95-98.
23. Karson C.N. Spontaneous eye-blink rates and dopaminergic systems. Brain. 106:1983;643-653.
24. Kendell R.E., Chalmers J.C., Platz C. Epidemiology of puerperal psychoses. British Journal of Psychiatry. 150:1987;662-673.
25. Laughren T.P., Brown W.A., Williams B.W. Serum prolactin and clinical state during neuroleptic treatment and withdrawal. American Journal of Psychiatry. 136:1979;108-110.
26. Lewine R. Schizophrenia: an amotivational syndrome in men. Canadian Journal of Psychiatry. 30:1985;316-318.
27. Lewine R.R.J., Strauss J.S., Gift T.E. Sex differences in age at first hospital admission for schizophrenia: fact or artifact? American Journal of Psychiatry. 138(4):1981;440-444.
28. Loranger A.W. Sex difference in age at onset of schizophrenia. Archives of General Psychiatry. 41:1984;157-161.
29. Lovestone S. Periodic psychosis associated with the menstrual cycle and increased blink rate. British Journal of Psychiatry. 161:1992;402-404.
30. Mancini A.M., Guitelman A., Vargas C.A., Debeljuk L., Aparicio N.J. Effect of sulpiride on serum prolactin levels in humans. Journal of Clinical Endocrinology and Metabolism. 42(1):1976;181-184.
31. Marder S.R., Hubbard J.W., Van Putten T., Midha K.K. Pharmacokinetics of long-acting injectable neuroleptic drugs: clinical implications. Psychopharmacology. 98:1989;433-439.
32. Martin, J.B., Reichlin, S., 1987. Regulation of prolactin secretion and its disorders. In: Davis, F.A. (Ed.), Clinical Neuroendocrinology. Philadelphia, pp. 201-231.
33. Nott P.N. Psychiatric illness following childbirth in Southampton: a case register study. Psychological Medicine. 12:1982;557-561.
34. Polishuk W.Z., Kulcsar S. Effects of chlorpromazine on pituitary function. Journal of Clinical Endocrinology and Metabolism. 16:1956;292-293.
35. Riecher-Rossler A., Hafner H., Stumbaum M., Maurer K., Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophrenia Bulletin. 20:1994;203-214.
36. Ripley H.S., Papanicolaou G.N. The menstrual cycle with vaginal smear studies in schizophrenia, depression and elation. American Journal of Psychiatry. 98:1942;567-573.
37. Rubin, R.T., 1987. Prolactin and schizophrenia. In: Meltzer, H. (Ed.), Psychopharmacology: The Third Generation of Progress. Raven Press, New York, pp. 803-808.
38. Sandison R.A., Whitelaw E., Currie J.D.C. Clinical trials with Mellaril (TP21) in the treatment of schizophrenia. Journal of Mental Science. 106:1960;732-741.
39. Seeman M.V. Interaction of sex, age and neuroleptic dose. Comprehensive Psychiatry. 24:1983;125-128.
40. Seeman M.V., Lang M. The role of estrogens in schizophrenia gender differences. Schizophrenia Bulletin. 16:1990;185-194.
41. Smith J.M., Dunn D.D. Sex differences in the prevalence of severe tardive dyskinesia. American Journal of Psychiatry. 136:1979;1080-1082.
42. Smith J.M., Oswald W.T., Kucharski L.T., Waterman L.J. Tardive dyskinesia: age and sex differences in hospitalized schizophrenics. Psychopharmacology. 58:1978;207-211.
43. Vogel P., Soddu G., Riecher A., Gattaz W.F. Effects of the menstrual cycle on the therapeutic response in schizophrenic patients. Pharmacopsychiatry. 25:1992;92.
44. Wyatt R.J., Alexander R.C., Egan M.F., Kirch D.G. Schizophrenia, just the facts: what do we know, how well do we know it? Schizophrenia Research. 1:1988;3-18.